# US 2024/0189339 A1 · MicroRNA (miRNA) and Downstream Targets for Diagnostic and Therapeutic Purposes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189339 A1
- Document ID: US20240189339A1
- Status: Published application
- Kind: A1
- Application number: 18/515,531
- Filed: 2023-11-21
- Published: 2024-06-13
- Earliest claimed: 2008-02-27
- Assignees: Julius-Maximilians-UniversitäT WüRzburg
- Applicants: Julius-Maximilians-Universitat Wurzburg
- Inventors: Thomas Thum; Johann Bauersachs; Stefan Engelhardt; Carina Gross
- Web page: https://patentgrep.com/patent/US20240189339A1

## CPC

- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 7/10: Antioedematous agents; Diuretics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/06: Antiarrhythmics
- A61P 9/08: Vasodilators for multiple indications
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/04: for non-specific disorders of the connective tissue
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/14: for RNA viruses
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/113: targeting other non-coding nucleic acids, e.g. antagomirs
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/141: MicroRNAs, miRNAs
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/3233: Morpholino-type ring
- C12N 2310/345: having at least two different backbone modifications
- C12N 2310/3515: Lipophilic moiety, e.g. cholesterol
- C12N 2310/3517: Marker; Tag
- C12N 2320/31: Combination therapy
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

In some embodiments, the invention is directed to a method for diagnosing fibrosis and/or fibrosis related diseases and to a method for screening a pharmaceutically active compound for the treatment of fibrosis and/or fibrosis related diseases. The present invention further relates to compositions for use in the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions modulate the activity of a miRNA for the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions inhibit the activity of miR-21 for the treatment, amelioration, and/or prevention of fibrosis.

## Claims

### Claim at position 1

1-139. (canceled)

### Claim 140

A method for diagnosing fibrosis comprising measuring the expression of miR-21 in a sample from a patient supposed to suffer from fibrosis, wherein an elevated level of miR-21 in comparison to a control sample indicates fibrosis or a predisposition thereof.

### Claim 141 (depends on 140)

The method of claim 140 comprising contacting the sample with a modified oligonucleotide complementary to miR-21 (SEQ ID NO: 1).

### Claim 142 (depends on 141)

The method of claim 141, wherein each of a plurality of nucleosides of the modified oligonucleotide comprises a modified sugar.

### Claim 143 (depends on 142)

The method of claim 142, wherein each modified sugar is independently selected from a 2′-O-methoxyethyl sugar, a 2′-fluoro sugar, a 2′-O-methyl sugar, or a bicyclic sugar moiety.

### Claim 144 (depends on 141)

The method of claim 141, wherein the modified oligonucleotide consists of 12 to 30 linked nucleosides.

### Claim 145 (depends on 141)

The method of claim 141, wherein the nucleobase sequence of the modified oligonucleotide is at least 90% complementary to the nucleobase sequence of miR-21 (SEQ ID NO: 1).

### Claim 146 (depends on 141)

The method of claim 141, wherein the nucleobase sequence of the modified oligonucleotide is at least 95% complementary to the nucleobase sequence of miR-21 (SEQ ID NO: 1).

### Claim 147 (depends on 141)

The method of claim 141, wherein the nucleobase sequence of the modified oligonucleotide is 100% complementary to the nucleobase sequence of miR-21 (SEQ ID NO: 1).

### Claim 148

A method for screening a pharmaceutically active compound for the treatment and/or the prevention of fibrosis or a predisposition thereof, comprising
a) contacting a candidate substance with a sample comprising miR-21; and
b) determining the effect of the candidate substance on the sample;
wherein an alteration of miR-21 indicates that the candidate substance is a pharmaceutically active compound.

### Claim 149 (depends on 148)

The method of claim 148, wherein the candidate substance is a modified oligonucleotide complementary to miR-21 (SEQ ID NO: 1).

### Claim 150 (depends on 149)

The method of claim 149, wherein each of a plurality of nucleosides of the modified oligonucleotide comprises a modified sugar.

### Claim 151 (depends on 150)

The method of claim 150, wherein each modified sugar is independently selected from a 2′-O-methoxyethyl sugar, a 2′-fluoro sugar, a 2′-O-methyl sugar, or a bicyclic sugar moiety.

### Claim 152 (depends on 149)

The method of claim 149, wherein the modified oligonucleotide consists of 12 to 30 linked nucleosides.

### Claim 153 (depends on 149)

The method of claim 149, wherein the nucleobase sequence of the modified oligonucleotide is at least 90% complementary to the nucleobase sequence of miR-21 (SEQ ID NO: 1).

### Claim 154 (depends on 149)

The method of claim 149, wherein the nucleobase sequence of the modified oligonucleotide is at least 95% complementary to the nucleobase sequence of miR-21 (SEQ ID NO: 1).

### Claim 155 (depends on 149)

The method of claim 149, wherein the nucleobase sequence of the modified oligonucleotide is 100% complementary to the nucleobase sequence of miR-21 (SEQ ID NO: 1).
